A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Sponsored by Alnylam Pharmaceuticals
About this trial
Last updated a month ago
Study ID
ALN-TTRSC02-007
Status
Enrolling by invitation
Type
Interventional
Phase
Phase 3
Placebo
No
Accepting
18+ Years
All
Not accepting
Healthy Volunteers
Trial Timing
Started 7 months ago
What is this trial about?
The purpose of this study is to obtain safety, efficacy, and pharmacodynamic data on the
use of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy who continued on
extended use of vutrisiran, or switched from patisiran.
What are the participation requirements?
Inclusion Criteria
- Patients who are participating in the patisiran parent studies ALN-TTR02-011 or ALN-TTR02-014 or who have completed the 24-month OLE Period in the vutrisiran parent study ALN-TTRSC02-003
Exclusion Criteria
- Has permanently discontinued study drug administration while participating in the parent studies, ALN-TTR02-011, ALN-TTR02-014, or ALN-TTRSC02-003
- Future or current participation in another investigational device or drug study, scheduled to occur during this study
- Has other medical conditions or comorbidities which, in the opinion of the Investigator, would interfere with study compliance or data interpretation